Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) Enterprise Value (2021 - 2025)

Bioregenx has reported Enterprise Value over the past 5 years, most recently at -$69383.0 for Q4 2025.

  • For Q4 2025, Enterprise Value fell 18.8% year-over-year to -$69383.0; the TTM value through Dec 2025 reached -$69383.0, down 18.8%, while the annual FY2025 figure was -$69383.0, 18.8% down from the prior year.
  • Enterprise Value for Q4 2025 was -$69383.0 at Bioregenx, down from -$46947.0 in the prior quarter.
  • Over five years, Enterprise Value peaked at -$676.0 in Q4 2022 and troughed at -$125402.0 in Q4 2023.
  • A 5-year average of -$46983.0 and a median of -$46947.0 in 2025 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: surged 97.22% in 2022 and later tumbled 18450.59% in 2023.
  • Year by year, Enterprise Value stood at -$24358.0 in 2021, then surged by 97.22% to -$676.0 in 2022, then tumbled by 18450.59% to -$125402.0 in 2023, then soared by 53.43% to -$58404.0 in 2024, then dropped by 18.8% to -$69383.0 in 2025.
  • Business Quant data shows Enterprise Value for BRGX at -$69383.0 in Q4 2025, -$46947.0 in Q3 2025, and -$46456.0 in Q2 2025.